Compare AFRM & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AFRM | ILMN |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3B | 26.7B |
| IPO Year | 2020 | 2000 |
| Metric | AFRM | ILMN |
|---|---|---|
| Price | $79.05 | $190.40 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 25 | 17 |
| Target Price | $84.52 | ★ $124.24 |
| AVG Volume (30 Days) | ★ 3.2M | 1.9M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 108.98 | ★ 170.87 |
| EPS | 0.90 | ★ 2.22 |
| Revenue | $3,224,412,000.00 | ★ $4,343,000,000.00 |
| Revenue This Year | $30.78 | $6.47 |
| Revenue Next Year | $23.95 | $5.58 |
| P/E Ratio | $87.00 | ★ $86.75 |
| Revenue Growth | ★ 38.80 | N/A |
| 52 Week Low | $42.10 | $88.00 |
| 52 Week High | $100.00 | $207.00 |
| Indicator | AFRM | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 55.88 | 50.35 |
| Support Level | $71.24 | $117.64 |
| Resistance Level | $79.79 | $196.66 |
| Average True Range (ATR) | 3.44 | 7.76 |
| MACD | 0.36 | -1.66 |
| Stochastic Oscillator | 82.44 | 22.18 |
Founded in 2012, Affirm is a market leader in the buy now, pay later space with around $36 billion in transaction volume in fiscal 2025. Affirm offers both zero-interest financing, which is merchant subsidized, and interest-bearing loans, which function as personal loans that are approved on a per-transaction basis. Over 70% of Affirm's transaction volume comes from its interest-bearing loans, which also constitute the majority of its revenue. Affirm primarily operates in the United States, which accounted for more than 95% of its revenue in 2025, but it has also expanded to Canada and the United Kingdom.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.